2012 - Fellow of the American Association for the Advancement of Science (AAAS)
Member of the Association of American Physicians
Hagop M. Kantarjian spends much of his time researching Internal medicine, Leukemia, Gastroenterology, Myeloid leukemia and Surgery. Hagop M. Kantarjian has researched Internal medicine in several fields, including Immunology and Oncology. His Leukemia research is multidisciplinary, incorporating elements of Myeloid, Myelodysplastic syndromes and Pharmacology.
Within one scientific family, he focuses on topics pertaining to Chemotherapy under Gastroenterology, and may sometimes address concerns connected to Acute promyelocytic leukemia. His studies deal with areas such as Adverse effect and Fms-Like Tyrosine Kinase 3 as well as Myeloid leukemia. Hagop M. Kantarjian works mostly in the field of Chronic myelogenous leukemia, limiting it down to topics relating to Philadelphia chromosome and, in certain cases, Acute lymphocytic leukemia, as a part of the same area of interest.
Hagop M. Kantarjian mainly investigates Internal medicine, Oncology, Myeloid leukemia, Gastroenterology and Leukemia. His work carried out in the field of Internal medicine brings together such families of science as Surgery and Immunology. His Oncology research is multidisciplinary, incorporating perspectives in Transplantation, Cancer, Myelodysplastic syndromes and Decitabine.
He combines subjects such as Tyrosine kinase and Bone marrow with his study of Myeloid leukemia. His studies in Gastroenterology integrate themes in fields like Refractory, Phases of clinical research, Adverse effect, Neutropenia and Myelofibrosis. His biological study spans a wide range of topics, including Myeloid and Pharmacology.
Hagop M. Kantarjian focuses on Internal medicine, Oncology, Myeloid leukemia, Cancer research and In patient. His work on Internal medicine is being expanded to include thematically relevant topics such as Gastroenterology. The Oncology study combines topics in areas such as Chemotherapy, Blinatumomab, Lymphoblastic Leukemia, Decitabine and Transplantation.
His work deals with themes such as Refractory, Myeloid, Azacitidine, Venetoclax and Bone marrow, which intersect with Myeloid leukemia. Hagop M. Kantarjian interconnects Tyrosine kinase, Mutant and Stem cell in the investigation of issues within Cancer research. The various areas that Hagop M. Kantarjian examines in his Leukemia study include Cancer and Clinical trial.
Internal medicine, Oncology, Myeloid leukemia, Leukemia and Gastroenterology are his primary areas of study. His Oncology research integrates issues from Hematopoietic stem cell transplantation, Transplantation, Phases of clinical research, Philadelphia chromosome and Blinatumomab. His Philadelphia chromosome research includes elements of Nilotinib, Ponatinib and Dasatinib.
His research in Myeloid leukemia focuses on subjects like Azacitidine, which are connected to Febrile neutropenia and Myelodysplastic syndromes. His Leukemia research incorporates themes from Survival rate, Cancer and Clinical trial. His Gastroenterology study combines topics from a wide range of disciplines, such as Hypomethylating agent and Bone marrow.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia
Brian J. Druker;Moshe Talpaz;Debra J. Resta;Bin Peng.
The New England Journal of Medicine (2001)
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
Stephen G. O'Brien;François Guilhot;Richard A. Larson;Insa Gathmann.
The New England Journal of Medicine (2003)
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
Brian J. Druker;François Guilhot;Stephen G. O'brien;Insa Gathmann.
The New England Journal of Medicine (2006)
Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia
Timothy J. Ley;Christopher Miller;Li Ding;Benjamin J. Raphael.
The New England Journal of Medicine (2013)
Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome
Brian J. Druker;Charles L. Sawyers;Hagop M Kantarjian;Debra J. Resta.
The New England Journal of Medicine (2001)
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia
Hagop M Kantarjian;Charles Sawyers;Andreas Hochhaus;Francois Guilhot.
The New England Journal of Medicine (2002)
Revised International Prognostic Scoring System for Myelodysplastic Syndromes
Peter L. Greenberg;Heinz Tuechler;Julie Schanz;Guillermo Sanz.
Blood (2012)
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
Michele Baccarani;Michael W. Deininger;Gianantonio Rosti;Andreas Hochhaus.
Blood (2013)
A Tyrosine Kinase Created by Fusion of the PDGFRA and FIP1L1 Genes as a Therapeutic Target of Imatinib in Idiopathic Hypereosinophilic Syndrome
Jan Cools;Jan Cools;Daniel J. DeAngelo;Jason Gotlib;Elizabeth H. Stover.
The New England Journal of Medicine (2003)
Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias
Moshe Talpaz;Neil P. Shah;Hagop M Kantarjian;Nicholas Donato.
The New England Journal of Medicine (2006)
Profile was last updated on December 6th, 2021.
Research.com Ranking is based on data retrieved from the Microsoft Academic Graph (MAG).
The ranking h-index is inferred from publications deemed to belong to the considered discipline.
If you think any of the details on this page are incorrect, let us know.
Augusta University
The University of Texas MD Anderson Cancer Center
The University of Texas MD Anderson Cancer Center
The University of Texas MD Anderson Cancer Center
University of California, Irvine
The University of Texas MD Anderson Cancer Center
The University of Texas MD Anderson Cancer Center
The University of Texas MD Anderson Cancer Center
The University of Texas MD Anderson Cancer Center
The University of Texas MD Anderson Cancer Center
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: